scholarly journals Lxrα Regulates the Androgen Response in Prostate Epithelium

Endocrinology ◽  
2012 ◽  
Vol 153 (7) ◽  
pp. 3211-3223 ◽  
Author(s):  
Emilie Viennois ◽  
Teresa Esposito ◽  
Julie Dufour ◽  
Aurélien Pommier ◽  
Stephane Fabre ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Molecular Mechanisms ◽  
Fold Increase ◽  
Prostatic Hyperplasia ◽  
Vesicular Trafficking ◽  
Ventral Prostate ◽  
Mouse Prostate ◽  
Prostate Epithelium ◽  
Prostatic Ducts

Benign prostatic hyperplasia is a nonmalignant enlargement of the prostate that commonly occurs in older men. We show that liver X receptor (Lxr)-α knockout mice (lxrα−/−) develop ventral prostate hypertrophy, correlating with an overaccumulation of secreted proteins in prostatic ducts and an alteration of vesicular trafficking in epithelial cells. In the fluid of the lxrα−/− prostates, spermine binding protein is highly accumulated and shows a 3000-fold increase of its mRNA. This overexpression is mediated by androgen hypersensitivity in lxrα−/− mice, restricted to the ventral prostate. Generation of chimeric recombinant prostates demonstrates that Lxrα is involved in the establishment of the epithelial-mesenchymal interactions in the mouse prostate. Altogether these results point out the crucial role of Lxrα in the homeostasis of the ventral prostate and suggest lxrα−/− mice may be a good model to investigate the molecular mechanisms of benign prostatic hyperplasia.

scholarly journals The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review

2020 ◽  
Vol 7 (3) ◽  
pp. 191-202 ◽  
Author(s):  
Renee E. Vickman ◽  
Omar E. Franco ◽  
Daniel C. Moline ◽  
Donald J. Vander Griend ◽  
Praveen Thumbikat ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Prostate Development

scholarly journals Pharmacological Effects and Potential Clinical Usefulness of Polyphenols in Benign Prostatic Hyperplasia

Molecules ◽  
2021 ◽  
Vol 26 (2) ◽  
pp. 450
Author(s):  
Kensuke Mitsunari ◽  
Yasuyoshi Miyata ◽  
Tomohiro Matsuo ◽  
Yuta Mukae ◽  
Asato Otsubo ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Molecular Mechanisms ◽  
Prostatic Hyperplasia ◽  
Pathological Conditions ◽  
Urinary Tract Symptoms ◽  
Anti Inflammatory ◽  
Lower Urinary

Benign prostatic hyperplasia (BPH) is arguably the most common benign disease among men. This disease is often associated with lower urinary tract symptoms (LUTS) in men and significantly decreases the quality of life. Polyphenol consumption reportedly plays an important role in the prevention of many diseases, including BPH. In recent years, in addition to disease prevention, many studies have reported the efficacy and safety of polyphenol treatment against various pathological conditions in vivo and in vitro. Furthermore, numerous studies have also revealed the molecular mechanisms of the antioxidant and anti-inflammatory effects of polyphenols. We believe that an improved understanding of the detailed pharmacological roles of polyphenol-induced activities at a molecular level is important for the prevention and treatment of BPH. Polyphenols are composed of many members, and their biological roles differ. In this review, we first provide information regarding the pathological roles of oxidative stress and inflammation in BPH. Next, the antioxidant and anti-inflammatory effects of polyphenols, including those of flavonoids and non-flavonoids, are discussed. Finally, we talk about the results and limitations of previous clinical trials that have used polyphenols in BPH, with particular focus on their molecular mechanisms of action.

ROLE OF ALPHA1-ADRENOCEPTOR SUBTYPE IN PROSTATIC GROWTH IN A BENIGN PROSTATIC HYPERPLASIA MODEL RAT

2008 ◽  
Vol 179 (4S) ◽  
pp. 451-451 ◽  
Author(s):  
Yoshiyuki Kojima ◽  
Shoichi Sasaki ◽  
Yutaro Hayashi ◽  
Kenjiro Kohri ◽  
Nobuyuki Oda ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Prostatic Growth

scholarly journals Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

2020 ◽  
Vol 10 (2) ◽  
pp. 15-25
Author(s):  
Amrallah A. Mohammed ◽  
Hanna M. Ibrahim ◽  
Hanna A. Atwa ◽  
Ayman Elshentenawy ◽  
Amira Elwan
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Cyclin D1 ◽  
Tumor Stage ◽  
Prostatic Hyperplasia ◽  
Common Finding ◽  
Tissue Sampling ◽  
Benign Lesions ◽  
Significant Difference

AbstractBackgroundDisturbance in cell cycle regulatory genes is a common finding among many types of cancers. The aim of this study is to evaluate the role of cyclin D1 and DJ-1 in benign prostatic hyperplasia (BPH) and prostate cancer (PC).MethodThe current study enclosed 40 patients diagnosed with PC and 40 cases of BPH. The expression level of cyclin D1 and DJ-1 were evaluated by immunohistochemistry (IHC). Cyclin D1 scored depending on the percentage of stained nuclear tumor cells. While scoring of DJ-1 was based on intensity. The results were correlated with clinicopathological features and outcome.ResultsIn the PC group, cyclin D1 was detected in 95% and overexpressed in 42.5%, DJ-1 was positively stained in 85% and overexpressed in 47.5%. Meanwhile, in the BPH group, cyclin D1 was not detected and DJ-1 stained in only 2.5%. There was a statistically significant difference in Gleason score (GS), tumor stage, size, and treatment failure (p =< 0.001). In the terms of PC diagnosis prediction, although cyclin D1 was more specific (100%), DJ-1 is more sensitive than cyclin D1 (80%, 70%, respectively) (p = 0.000).ConclusionsCyclin D1 and DJ-1 may emerge as a promising way for diagnosis of PC in certain circumstances, as the presence of insufficient tissue sampling, small foci of carcinoma or benign lesions mimic PC. This is in addition to the known role of cyclin D1 and DJ-1 in PC prognosis.

Role of Prostate Ultrasonography to Predict The Efficacy of Bipolar Prostatectomy in Benign Prostatic Hyperplasia

2021 ◽  
Author(s):  
Ali Ibrahim ◽  
Diaaeldin Taha ◽  
Mona Talaat ◽  
Hossam Nabeeh ◽  
Tarek Abdelbaky
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Clinical Outcomes ◽  
Transurethral Resection ◽  
Erectile Function ◽  
Urine Volume ◽  
Close Correlation ◽  
Prostatic Hyperplasia ◽  
Significant Difference ◽  
Maximum Improvement

Abstract Background: We evaluated the role of prostatic ultrasonography to predict the clinical outcomes of Bipolar Transurethral resection of the prostate. Methods: 109 Patients complaining of lower urinary tract symptoms (LUTs) due to Benign Prostatic Hyperplasia (BPH) were evaluated preoperatively and postoperatively (at 1, 3, and 6 months) using ultrasonography (pelvi-abdominal and transrectal ), the International Prostate Symptom Score (IPSS), uroflowmetry, post-void residual urine volume (PVR), ejaculatory domain, and the erectile function domain of the International Index of Erectile Function (IIEF-ED). The safety of the procedure was assessed by Modified Clavien classification of complications.Result: There was a close correlation between residual tissue of prostate detected by ultrasonography and clinical outcomes. The prostate volume was significantly decreased postoperatively with a concomitant significant improvement of IPSS, Qmax, and PVR over six months of follow-up (P <0.001 ). 57.8 % of the cases in this study were sexually active, and there was no significant difference in the IIEF-ED score between preoperative and postoperative evaluation.Conclusion: Prostate ultrasonography has a significant predictive value as a single investigating tool to evaluate the clinical outcomes after bipolar transurethral resection of the prostate (TURP). The maximum improvement in IPSS and ultrasonographic measurements were detected at six months postoperatively.

scholarly journals Ghrelin Aggravates Prostate Enlargement in Rats with Testosterone-Induced Benign Prostatic Hyperplasia, Stromal Cell Proliferation, and Smooth Muscle Contraction in Human Prostate Tissues

2019 ◽  
Vol 2019 ◽  
pp. 1-14 ◽  
Author(s):  
Xiaolong Wang ◽  
Yiming Wang ◽  
Christian Gratzke ◽  
Christian Sterr ◽  
Qingfeng Yu ◽  
...  
Keyword(s):  
Smooth Muscle ◽  
Benign Prostatic Hyperplasia ◽  
Muscle Contraction ◽  
Stromal Cell ◽  
Molecular Mechanisms ◽  
Smooth Muscle Contraction ◽  
Prostatic Hyperplasia ◽  
Human Prostate ◽  
Mrna Levels ◽  
Prostate Enlargement

Epidemiologic studies revealed a context between lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and metabolic syndrome. However, molecular mechanisms underlying this relationship are largely unknown. Prostate enlargement and increased prostate smooth muscle tone are important factors in the pathophysiology of LUTS suggestive of BPH. In the present study, we studied effects of the metabolic hormone ghrelin on prostate enlargement in rats with experimentally induced BPH, growth of cultured stromal cells from human prostate (WPMY-1), and smooth muscle contraction of human prostate tissues. Ghrelin (20 nmol/kg daily, p.o., 2 weeks) increased prostate size in rats with testosterone-induced BPH. Microarray identified 114 ghrelin-upregulated genes (2-fold or more) in these prostates, with possible roles in growth, smooth muscle contraction, or metabolism. 12 genes were selected for further analyses. In human prostate tissues, mRNA levels of 11 of them correlated positively with ghrelin receptor (GHSR) expression, but only two with the degree of BPH. Accordingly, no correlation was evident between GHSR expression level and BPH in human prostate tissues. In WPMY-1 cells, the GHRS agonist MK0677 upregulated 11 of the selected genes. MK0677 induced proliferation of WPMY-1 cells, shown by EdU assay, colony formation, proliferation markers, flow cytometry, and viability. In myographic measurements, GHSR agonists enhanced contractions of human prostate strips. Together, ghrelin may aggravate prostate enlargement, stromal cell growth, and prostate smooth muscle contraction in BPH. Ghrelin may deteriorate urethral obstruction independently from BPH, qualifying the ghrelin system as an attractive new target to be tested for LUTS treatment in BPH.

Sign in / Sign up

Export Citation Format

Share Document